The invention relates to a compound composed of a metal ion, or metal, such as a radiopharmaceutical from a metal radio-nuclide, and a marker precursor, which is constructed of a bi-functional, macrocyclic chelator, a spacer, a linker, and at least two targeting vectors. For this purpose, the chelator comprises preferably a 9-, 10-, 11-, 12-, 14-, or 16-link polyazamacrocycle, preferably further complexing donors. The spacer is preferably constructed of linear, branched, or hetero-substituted, saturated, unsaturated, or aromatic hydrocarbons, or of sugars. Targeting vectors are preferably proteinogenic or synthetic a-amino-carboxylic acids. The metal radio-nuclides are preferably 2-, 3-, or 4-valent, wherein the gallium radio-isotopes 65Ga, 66Ga, 67Ga, 68Ga, 70Ga, and 72Ga are preferred. The radiopharmaceutical is suitable for the nuclear medical diagnosis of tumors by means of positron emission tomography (PET), and by means of single photon emission computer tomography (SPECT). In endo-radiotherapy (ERT) the radiopharmaceutical is incorporated directly or systemically into the target tissue.
